Anti-IgE antibodies
The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of IgE with the FcεRI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair®). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the Cε2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the Cε2 domain of IgE) and/or the ability to disassociate IgE from the FcεRI receptor for instance at pharmaceutically-relevant concentrations. In one aspect, improved or novel treatments for IgE mediated disorders are disclosed in which IgE is targeted (for instance free IgE and/or IgE complexed with the FcεRI receptor).
1. A method for treating a disease in a human subject in need thereof, the method comprising administering to the subject an effective amount of an anti-IgE antibody, or antigen binding agent or a pharmaceutical composition comprising the anti-IgE antibody or antigen binding agent and one or more of a pharmaceutically acceptable excipient, diluent or carrier, wherein the anti-IgE antibody, or antigen binding agent comprises a heavy chain variable region comprising complementarity determining regions: CDR-H1 comprising SEQ ID NO:14, CDR-H2 comprising SEQ ID NO:16, CDR-H3 comprising SEQ ID NO: 18, and a light chain variable region comprising complementarity determining regions: CDR-L1 comprising SEQ ID NO:29, CDR-L2 comprising SEQ ID NO:50 or 51, and CDR-L3 comprising SEQ ID NO: 33.
2. The method of claim 1 , wherein the disease is associated with a complex of human IgE and FcεRI.
3. The method of claim 2 , wherein the treatment is through the disassociation of the complex of human IgE and FcεRI and the binding of human IgE by the anti-IgE antibody, or antigen binding agent.
4. The method of claim 1 , wherein the disease is: allergy; allergic asthma; severe asthma; moderate asthma; chronic spontaneous urticaria; chronic idiopathic urticaria; perennial allergic rhinitis; seasonal allergic rhinitis; acute asthma exacerbations; acute bronchospasm; status asthmaticus; hyper IgE syndrome; allergic bronchopulmonary aspergillosis; food allergy; atopic dermatitis; allergic rhinitis; bee venom sensitivity; idiopathic anaphylaxis; peanut allergy; latex allergy; inflammatory skin diseases; urticaria; cutaneous mastocytosis; systemic mastocytosis; eosinophil-associated gastrointestinal disorder; bullous pemphigoid; interstitial cystitis; nasal polyps; idiopathic angioedema; or non-allergic asthma.
5. The method of claim 1 , wherein the anti-IgE antibody, or antigen binding agent is selected from the group consisting of a Fab fragment, modified Fab′ fragment, Fab′ fragment, F(ab′) 2 fragment, Fv, scFv, scAb, a diabody, bispecific antibody, triabody, FabFv, Fab-Fv-Fv, tribody, and a (Fab-Fv) 2 -Fc.
6. The method of claim 5 , wherein the anti-IgE antibody, or antigen binding agent comprises an scFv comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a CDR-H1 comprising SEQ ID NO: 152, a CDR-H2 comprising SEQ ID NO: 153, and a CDR-H3 comprising SEQ ID NO: 154 and the light chain variable region comprises a CDR-L1 comprising SEQ ID NO: 155, a CDR-L2 comprising SEQ ID NO: 156, and a CDR-L3 comprising SEQ ID NO: 157.
7. The method of claim 5 , wherein the anti-IgE antibody is a Fab fragment comprising a heavy chain variable region and a light chain variable region, wherein:
a) the heavy chain variable region comprises a CDR-H1 comprising SEQ ID NO: 14, a CDR-H2 comprising SEQ ID NO: 16, and a CDR-H3 comprising SEQ ID NO: 18 and the light chain variable region comprises a CDR-L1 comprising SEQ ID NO: 29, a CDR-L2 comprising SEQ ID NO: 50, a CDR-L3 comprising SEQ ID NO: 33 and a framework region FW-L3 comprising SEQ ID NO: 131 or 138; or
b) the heavy chain variable region comprises SEQ ID NO: 1 and the light chain variable region comprises SEQ ID NO: 132 or 139.
8. The method of claim 6 , wherein the heavy chain variable region and the light chain variable are linked by a linker comprising SEQ ID NO:151.
9. A method for treating a disease in a human subject in need thereof, the method comprising administering to the subject an effective amount of an anti-IgE antibody, or antigen binding agent or a pharmaceutical composition comprising the anti-IgE antibody or antigen binding agent and one or more of a pharmaceutically acceptable excipient, diluent or carrier, wherein the anti-IgE antibody, or antigen binding agent comprises a heavy chain variable region and a light chain variable region, wherein:
a. the heavy chain variable region comprises a CDR-H1 comprising SEQ ID NO:14, a CDR-H2 comprising SEQ ID NO: 16 and a CDR-H3 comprising SEQ ID NO:18 and the light chain variable region comprises a CDR-L1 comprising SEQ ID NO:29, a CDR-L2 comprising SEQ ID NO:50, a CDR-L3 comprising SEQ ID NO:33 and a framework region FW-L3 comprising SEQ ID NO: 131 or 138; or
b. the heavy chain variable region comprises SEQ ID NO: 1 and the light chain variable region comprises SEQ ID NO: 132 or 139.
10. The method of claim 9 , wherein the anti-IgE antibody, or antigen binding agent further comprising a light chain constant region, wherein the light chain variable region and the light chain constant region VL-CL comprise SEQ ID NO:137 or 145.
11. The method of claim 9 , wherein the anti-IgE antibody, or antigen binding agent further comprises a heavy chain constant region, CH1.
12. The method of claim 9 , wherein the heavy chain variable region and heavy chain constant region, VH-CH1 comprise SEQ ID NO: 5.